Investigation of cytotoxic effect and biological activity of two novel derivatives of cisplatin on breast cancer cell lines (skbrt-3, mcf-7, mda-mb-231 and mba-mb- 468)

With 1.36 million new cases in worldwide each year, breast cancer (BC) is the most common malignancy in females. Besides surgery and radiation, several systemic treatment i.e. chemotherapy andhormonal are also used to treat cancer. We previously described the synthesis of some new cisplatin derivatives with comparable anti-cancer activities to Cisplatin as a standard drug. In the present study,we extended the cytotoxic studies of two potent of these compounds in different types of human breast cancers.Four breast cancer cell lines including SKBRT-3, MCF-7, MDA-MB-231 and MBA-MB-468were grown in RPMI-1640 medium supplemented with 10-20% FBS and penicillin-streptomycin. The cytotoxic effects of different concentrations (1 μM to 100 μM) of both Pt compounds were determinedby a standard MTT cytotoxic assay during 24 hours The absorbance at 492 nm was measured by ELISA reader. The tests were repeated in triplicate manner. The percentage of viable cell was calculatedand dose-response curve were plotted to obtain the concentrations in which 50% of the cells were killed (IC50). The cytotoxic activities of Pt compounds were compared to Cisplatin as a positivecontrol.Our result showed that in comparison to Cisplatin, two new Pt compounds had more cytotoxic effects in all different types of BC cell lines. Pt1 was the most effective compound (Pt1 IC50s 17.96 ±0.35, 7.17 ± 0.13, 7.93 ± 0.88 and 25.08 ± 3.85 μM vs. Cisplatin IC50s 83.2 ± 1.2, 72.24 ± 0.88, 60.12 ± 1.2 and 190.93 ± 0.28 μM in SKBR-3, MCF-7, MDA-MB-231 and MBA-MB-468, respectively). According to our results, these two Pt compounds could be introduces as new potential chemotropic agents in all types of breast cancer in the clinic. However, more safety and functional in vivo studies areneeded.

کلیدواژه ها:

Breast Cancer ، Cell and Cancer ، Cancer Treatment and Management ، Drugs and Cancer ، Chemotherapy